A Successful Chemoembolization of a Retroperitoneal Soft Tissue Sarcoma: A Case Report.

Autor: David Filho WJ; Oncology, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.; Oncology, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil., Uchiyama AAT; Oncology, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Marchon C; Oncology, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Lopes LMD; Oncology, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil., Baccarin ALC; Oncology, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil., de Fina B; Vascular, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil., Dos Santos RV; Vascular, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil., Galastri FL; Vascular, Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Case reports in oncology [Case Rep Oncol] 2021 Nov 25; Vol. 14 (3), pp. 1691-1697. Date of Electronic Publication: 2021 Nov 25 (Print Publication: 2021).
DOI: 10.1159/000520381
Abstrakt: Retroperitoneal sarcomas are rare entities. They have a tendency of growing slowly, rendering the patient apparently healthy for long periods of time, before diagnosis. Besides, they have a worse prognosis than sarcomas arising in extremities, with a higher local recurrence rate and lower 5-year survival rate. We describe a case of a 71-year-old male patient, who had a very well succeeded treatment of a large retroperitoneal sarcoma with the combination of chemoembolization, systemic chemotherapy, surgery, and radiation therapy. Initially, it was noticed in an incidental way he had a large retroperitoneal mass (15 cm × 10 cm × 9.2 cm) through magnetic resonance, when he was 63. The case was considered inoperable by the treating physicians. After neoadjuvant therapy, the residual tumor could be completely excised by the responsible surgeon. With a follow-up of >5 years, since the end of treatment, the patient remains in complete remission and, probably, cured from his illness. Large retroperitoneal sarcomas are still a great challenge for oncologists. According to the medical literature, chemoembolization can benefit some patients, but most of them in a palliative setting. In our report, we believe its contribution was critical for a great outcome. In selected cases, it is possible this procedure may be an additional therapeutic modality, as part of a multidisciplinary approach.
Competing Interests: The authors have no conflicts of interest to be declared.
(Copyright © 2021 by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje